国际内分泌代谢杂志
國際內分泌代謝雜誌
국제내분비대사잡지
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2014年
4期
245-247
,共3页
叶婧%张以勤%罗浩%王玉新
葉婧%張以勤%囉浩%王玉新
협청%장이근%라호%왕옥신
肾炎康复片%糖尿病肾病%内皮素-1%血栓调节蛋白%血管内皮生长因子
腎炎康複片%糖尿病腎病%內皮素-1%血栓調節蛋白%血管內皮生長因子
신염강복편%당뇨병신병%내피소-1%혈전조절단백%혈관내피생장인자
Shenyan Kangfu Pian%Diabetic nephropathy%Endothelin-1%Thrombomodulin%Vascular endothelial growth factor
目的 探讨肾炎康复片对早期糖尿病肾病患者血浆内皮素-1(ET-1)、血栓调节蛋白(TM)及血管内皮生长因子(VEGF)水平的影响.方法 入选96例早期糖尿病肾病患者,采用随机数字表法随机分为两组,每组48例,对照组接受常规治疗(阿司匹林肠溶片100 mg/d,qd;阿托伐他汀钙片20 mg/d,qn;厄贝沙坦片150mg/d,qd;降血糖药物或胰岛素控制血糖,疗程12周).治疗组在常规治疗基础上加用肾炎康复片治疗(5片/次,3次/d,疗程12周).ELISA法测定两组患者治疗前、后血浆ET-1、TM及VEGF水平.结果 对照组治疗前血浆ET-1、TM及VEGF水平分别为(58.1±15.2) ng/L、(77.4±15.0) ng/L、(389.8±68.3) ng/L,治疗后均有明显下降,分别为(36.5±9.3) ng/L、(52.3±11.9) ng/L、(227.6±45.9) ng/L(t=2.921,2.752,2.818,P＜0.01).治疗组治疗前血浆ET-1、TM及VEGF水平分别为(57.3±14.4) ng/L、(78.4±16.2) ng/L、(386.5±66.6) ng/L,治疗后亦均有明显下降,分别为(22.7±7.6) ng/L、(31.2±8.7) ng/L、(157.1±38.2)ng/L(t =2.877、2.699、2.901,P＜0.01).治疗组下降更为明显,与对照组相比差异有统计学意义(P均＜0.05).结论 肾炎康复片能降低早期糖尿病肾病患者血浆ET-1、TM及VEGF水平,改善血管内皮功能.
目的 探討腎炎康複片對早期糖尿病腎病患者血漿內皮素-1(ET-1)、血栓調節蛋白(TM)及血管內皮生長因子(VEGF)水平的影響.方法 入選96例早期糖尿病腎病患者,採用隨機數字錶法隨機分為兩組,每組48例,對照組接受常規治療(阿司匹林腸溶片100 mg/d,qd;阿託伐他汀鈣片20 mg/d,qn;阨貝沙坦片150mg/d,qd;降血糖藥物或胰島素控製血糖,療程12週).治療組在常規治療基礎上加用腎炎康複片治療(5片/次,3次/d,療程12週).ELISA法測定兩組患者治療前、後血漿ET-1、TM及VEGF水平.結果 對照組治療前血漿ET-1、TM及VEGF水平分彆為(58.1±15.2) ng/L、(77.4±15.0) ng/L、(389.8±68.3) ng/L,治療後均有明顯下降,分彆為(36.5±9.3) ng/L、(52.3±11.9) ng/L、(227.6±45.9) ng/L(t=2.921,2.752,2.818,P＜0.01).治療組治療前血漿ET-1、TM及VEGF水平分彆為(57.3±14.4) ng/L、(78.4±16.2) ng/L、(386.5±66.6) ng/L,治療後亦均有明顯下降,分彆為(22.7±7.6) ng/L、(31.2±8.7) ng/L、(157.1±38.2)ng/L(t =2.877、2.699、2.901,P＜0.01).治療組下降更為明顯,與對照組相比差異有統計學意義(P均＜0.05).結論 腎炎康複片能降低早期糖尿病腎病患者血漿ET-1、TM及VEGF水平,改善血管內皮功能.
목적 탐토신염강복편대조기당뇨병신병환자혈장내피소-1(ET-1)、혈전조절단백(TM)급혈관내피생장인자(VEGF)수평적영향.방법 입선96례조기당뇨병신병환자,채용수궤수자표법수궤분위량조,매조48례,대조조접수상규치료(아사필림장용편100 mg/d,qd;아탁벌타정개편20 mg/d,qn;액패사탄편150mg/d,qd;강혈당약물혹이도소공제혈당,료정12주).치료조재상규치료기출상가용신염강복편치료(5편/차,3차/d,료정12주).ELISA법측정량조환자치료전、후혈장ET-1、TM급VEGF수평.결과 대조조치료전혈장ET-1、TM급VEGF수평분별위(58.1±15.2) ng/L、(77.4±15.0) ng/L、(389.8±68.3) ng/L,치료후균유명현하강,분별위(36.5±9.3) ng/L、(52.3±11.9) ng/L、(227.6±45.9) ng/L(t=2.921,2.752,2.818,P＜0.01).치료조치료전혈장ET-1、TM급VEGF수평분별위(57.3±14.4) ng/L、(78.4±16.2) ng/L、(386.5±66.6) ng/L,치료후역균유명현하강,분별위(22.7±7.6) ng/L、(31.2±8.7) ng/L、(157.1±38.2)ng/L(t =2.877、2.699、2.901,P＜0.01).치료조하강경위명현,여대조조상비차이유통계학의의(P균＜0.05).결론 신염강복편능강저조기당뇨병신병환자혈장ET-1、TM급VEGF수평,개선혈관내피공능.
Objective To explore the effects of Shenyan Kangfu Pian on plasma concentrations of endothelin-1 (ET-1),thrombomodulin (TM) and vascular endothelial growth factor (VEGF) in patients with early diabetic nephropathy.Methods 96 patients with early diabetic nephropathy were randomly divided into control group (n =48) and treatment group(n =48)according to a random number table.Patients in control group were treated with routine drugs (aspirin tablet,100 mg/d qd ;atorvastatin tablet,20 mg/d qn;irbesartan tablet,150 mg/d qd;oral hypoglycemic agents or insulin).Patients in treatment group were treated with Shenyan Kangfu Pian (5 tablets,tid) and routine drugs for 12 weeks.Plasma ET-1,TM and VEGF were measured with enzyme linked immunosor-bent assay (ELISA).Results The level of plasma ET-1,TM and VEGF in control group were(58.1 ± 15.2)ng/L,(77.4 ± 15.0) ng/L and(389.8 ± 68.3) ng/L before treatment,and were also decreased significantly after treatment [(36.5 ± 9.3)ng/L,(52.3 ± 11.9) ng/L,(227.6 ± 45.9) ng/L,t =2.921,2.752,2.818,P ＜0.01].The level of plasma ET-1,TM and VEGF in treatment group were (57.3 ± 14.4) ng/L,(78.4 ± 16.2) ng/L and (386.5 ± 66.6) ng/L before treatment,and were also decreased significantly after treatment [(22.7 ± 7.6) ng/L,(31.2 ± 8.7) ng/L,(157.1 ± 38.2) ng/L,t =2.877,2.699,2.901,P＜0.01].The level of plasma ET-1,TM,VEGF in treatment group were lower than those in control group after treatment(all P＜0.05).Conclusion Shenyan Kangfu Pian can improve vascular endothelial cell function by decreasing the level of plasma ET-1,TM and VEGF in patients with early diabetic nephropathy.
